-
J Clin Oncol: Order of treatment of choice for BRAFV600 mutant metastatic melanoma
Time of Update: 2022-10-12
Secondary endpoints included 3-year overall survival, objective response rate, duration of response, progression-free survival, and safety.
Secondary endpoints included 3-year overall survival, objective response rate, duration of response, progression-free survival, and safety.
Secondary endpoints included 3-year overall survival, objective response rate, duration of response, progression-free survival, and safety.
-
Int J Radiat Oncol Biol Phys: How effective is IVH with or without brachytherapy in patients with very high-risk prostate cancer?
Time of Update: 2022-10-12
Very high-risk (VHR) prostate cancer (PC) is an aggressive subgroup with a high risk of long-range progression in which systematic intensive therapy with abiraterone or docetaxel reduces specific mortality (PCSM) and distal metastases (DM) in men receiving in vitro irradiation radiation therapy (EBRT) and androgen deprivation therapy (ADT).
-
European Radiology: Lineage plot of survival prognosis for triple-negative breast cancer
Time of Update: 2022-10-12
The nominative graph model proposed in this study integrates three variables of postoperative adjuvant chemotherapy, axillary lymph node load and malignant acoustic performance, and can be used as an effective imaging tool to predict the survival prognosis of patients with TNBC.
-
Trastuzumab subcutaneous preparation approved in China for administration in only 2-5 minutes!
Time of Update: 2022-10-12
It is worth mentioning that Roche Pharma China also disclosed that on July 27 this year, the domestic marketing application of Roche pertuzumab trastuzumab injection (subcutaneous injection) was accepted, which is a fixed-dose combination of subcutaneous preparations (trade name Phesgo®), which has previously been approved in the United States, the European Union and other countries and regions for the treatment of early and metastatic HER2-positive breast cancer patients.
-
【One case per day】 Liver metastases
Time of Update: 2022-10-12
The pathology of liver metastases is similar to the primary lesion, such as their blood supply is the same as that of the primary tumor2.
The pathology of liver metastases is similar to the primary lesion, such as their blood supply is the same as that of the primary tumor2.
-
A complete review of the nine major drug targets for non-small cell lung cancer
Time of Update: 2022-10-12
At present, EGFR-TKI has developed into the fourth generation, and a total of 8 drugs have been launched .
At present, EGFR-TKI has developed into the fourth generation, and a total of 8 drugs have been launched .
-
"Drink more hot water" The girlfriend and the scientist shook their heads when they heard it!
Time of Update: 2022-10-11
(Image source: Internet)But who would have thought that in the rapidly changing 21st century, the hot water, which is deeply loved by the Chinese people, has actually overturned!A report published by the International Agency for Research on Cancer (IARC) in "Lancet Oncology" showed for the first time that hot drinks above 65°C may cause esophageal cancer or throat cancer, which is a class 2A carcinogen (meaning "probably carcinogenic to humans").
-
European Radiology: Evaluation of response to yttrium-90 radioembolization in hepatocellular carcinoma using MRI
Time of Update: 2022-10-10
Recently, a study published in the journal European Radiology evaluated the diagnostic performance of gadoxetate disodium-enhanced MRI in predicting complete pathological necrosis (CPN) in HCC after TARE therapy using histopathology as a reference standard, for accurate clinical evaluation of treatment.
-
European Radiology: Evaluation of liver metastases by deep learning-based dual-energy CT image reconstruction
Time of Update: 2022-10-10
A study published in the journal European Radiology evaluated the image quality of 40-keV VMI reconstructed by a provider's diagnostic DLM in liver metastases compared to standard linear mixed images (simulated 100-KVp) and raw 40-keV VMI.
-
Director Zhang Jian: The latest clinical progress of HER2-positive breast cancer
Time of Update: 2022-10-10
I am personally cautious, because the distinction between HER2 positive and negative is mainly determined by the patient's treatment effect (mainly naked antibodies, such as trastuzumab) is affected by the driver gene, and we cannot be easily based on the particular benefit brought by new drugs.
-
European Radiology: Application of ultrasound elastography in predicting axillary lymph node status after neoadjuvant chemotherapy in breast cancer
Time of Update: 2022-10-10
Recently, a study published in European Radiology explored the value of combining axillary US and breast SWE in the detection of residual axillary LN metastases after NAC in patients with initially biopsy-proven node-positive breast cancer for an early clinical, accurate, and noninvasive assessment.
-
New exploration of treatment mode after CDK4/6i failure in HR+HER2- advanced breast cancer
Time of Update: 2022-10-10
DESTINY-Breast04 is a phase Ill study for HER2-low mBC, comparing the therapeutic effect of T-DXd and TPC (capecitabine, eribulin, gemcitabine, paclitaxel, nab-paclitaxel) single-agent chemotherapy, The proportion of patients who failed previous CDK4/6i therapy was 64%-71% .
-
Can antihypertensive drugs also curb pancreatic cancer?
Time of Update: 2022-10-08
" ACEI or ARB drugs are inexpensive, have low side effects, are widely available, and can improve survival in pancreatic cancer patients very well .
" ACEI or ARB drugs are inexpensive, have low side effects, are widely available, and can improve survival in pancreatic cancer patients very well .
-
Express all liver cancer metastases disappeared!
Time of Update: 2022-10-08
▲If you have any business needs, please long press to scan the QR code above, or▎Edited by WuXi AppTec Content TeamCan-Fite BioPharma announced today that its investigational liver cancer drug namodenoson has been approved in Romania as a compassionate use for the treatment of patients with advanced liver cancer .
-
European Radiology: How to use imaging methods to reduce the incidence of interval breast cancer?
Time of Update: 2022-10-08
In the double-reading program, women with false-positive screening results had an increased risk of breast cancer at intervals and cancers detected in successive rounds of screening .
-
Literature review on the treatment progress of HER2-positive advanced breast cancer
Time of Update: 2022-10-08
CLEOPATRA is a double-blind, randomized, placebo-controlled, phase III clinical trial study conducted in 204 research centers in 25 countries, which included 808 patients with HER2-positive advanced breast cancer.
-
Clin Cancer Res: Nivolumab in combination with docetaxel for advanced or recurrent NSCLC
Time of Update: 2022-10-08
conducted an open-label, randomized phase II/III study to evaluate nivolumab plus docetaxel combination therapy compared with nivolumab monotherapy in patients with previously treated ICI Efficacy and safety in treated non-small cell lung cancer (NSCLC) .
-
Cancer Sci: Safety and Efficacy of T-VEC in Japanese Patients with Advanced Melanoma - Phase I Study
Time of Update: 2022-10-08
The safety and efficacy of T-VEC in Japanese patients with unresectable stage IIIB-IV melanoma were evaluated in a phase I, multicenter, open-label, dose-declining study published in Cancer Sci .
-
Nat Commun: Novel drug candidates may use novel uptake strategies to target cancer cells in mice
Time of Update: 2022-10-08
Recently, in a research report titled "A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy" published in the international journal Nature Communications, scientists from the University of Michigan and other institutions have developed a new type of antibody through research.
-
Clin Cancer Res: A novel small molecule thymidylate synthase inhibitor CT900 in the treatment of high-grade serous ovarian cancer
Time of Update: 2022-10-08
A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer.
A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer.
